184 related articles for article (PubMed ID: 36907870)
21. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.
Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW
Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966
[TBL] [Abstract][Full Text] [Related]
22. BRIP1 variations analysis reveals their relative importance as genetic susceptibility factor for cervical cancer.
Ma XD; Cai GQ; Zou W; Huang YH; Zhang JR; Wang DT; Chen BL
Biochem Biophys Res Commun; 2013 Apr; 433(2):232-6. PubMed ID: 23473757
[TBL] [Abstract][Full Text] [Related]
23. A Novel Role for BRIP1/FANCJ in Neuronal Cells Health and in Resolving Oxidative Stress-Induced DNA Lesions.
Mani C; Acharya G; Kshirsagar S; Vijayan M; Khan H; Reddy PH; Palle K
J Alzheimers Dis; 2022; 85(1):207-221. PubMed ID: 34776453
[TBL] [Abstract][Full Text] [Related]
24. Helicase-inactivating
Kamal L; Pierce SB; Canavati C; Rayyan AA; Jaraysa T; Lobel O; Lolas S; Norquist BM; Rabie G; Zahdeh F; Levy-Lahad E; King MC; Kanaan MN
Cold Spring Harb Mol Case Stud; 2020 Oct; 6(5):. PubMed ID: 33028645
[TBL] [Abstract][Full Text] [Related]
25. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
Levran O; Attwooll C; Henry RT; Milton KL; Neveling K; Rio P; Batish SD; Kalb R; Velleuer E; Barral S; Ott J; Petrini J; Schindler D; Hanenberg H; Auerbach AD
Nat Genet; 2005 Sep; 37(9):931-3. PubMed ID: 16116424
[TBL] [Abstract][Full Text] [Related]
26. Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity.
Türke C; Horn S; Petto C; Labudde D; Lauer G; Wittenburg G
Int J Oncol; 2017 Jun; 50(6):2207-2220. PubMed ID: 28440438
[TBL] [Abstract][Full Text] [Related]
27. BRIP1 rs10744996C>A variant increases the risk of chronic obstructive pulmonary disease in the Mongolian population of northern China.
Wang J; Sun D; Lu W; Zhang Z; Zhang C; Hu K
Exp Physiol; 2020 Nov; 105(11):1950-1959. PubMed ID: 32851703
[TBL] [Abstract][Full Text] [Related]
28. Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.
Solyom S; Pylkäs K; Winqvist R
Fam Cancer; 2010 Dec; 9(4):537-40. PubMed ID: 20567916
[TBL] [Abstract][Full Text] [Related]
29. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
Suszynska M; Ratajska M; Kozlowski P
J Ovarian Res; 2020 May; 13(1):50. PubMed ID: 32359370
[TBL] [Abstract][Full Text] [Related]
30. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.
Monteiro LJ; Khongkow P; Kongsema M; Morris JR; Man C; Weekes D; Koo CY; Gomes AR; Pinto PH; Varghese V; Kenny LM; Charles Coombes R; Freire R; Medema RH; Lam EW
Oncogene; 2013 Sep; 32(39):4634-45. PubMed ID: 23108394
[TBL] [Abstract][Full Text] [Related]
31. Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.
Aravind Kumar M; Naushad SM; Narasimgu N; Nagaraju Naik S; Kadali S; Shanker U; Lakshmi Narasu M
Mol Biol Rep; 2018 Oct; 45(5):1413-1419. PubMed ID: 30136158
[TBL] [Abstract][Full Text] [Related]
32. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
33. Two tSNPs in BRIP1 are associated with breast cancer during TDT analysis.
Li X; Li Z; Yang M; Luo Y; Hu L; Xiao Z; Huang A; Huang J
Mol Genet Genomic Med; 2021 Feb; 9(2):e1578. PubMed ID: 33403820
[TBL] [Abstract][Full Text] [Related]
34. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer.
Song H; Ramus SJ; Kjaer SK; Hogdall E; Dicioccio RA; Whittemore AS; McGuire V; Hogdall C; Jacobs IJ; Easton DF; Ponder BA; Dunning AM; Gayther SA; Pharoah PD
PLoS One; 2007 Mar; 2(3):e268. PubMed ID: 17342202
[TBL] [Abstract][Full Text] [Related]
35. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
36. Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.
Ray AM; Zuhlke KA; Johnson GR; Levin AM; Douglas JA; Lange EM; Cooney KA
Br J Cancer; 2009 Dec; 101(12):2043-7. PubMed ID: 19935797
[TBL] [Abstract][Full Text] [Related]
37. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
38. CASP8, XRCC1, WRN, NF2, and BRIP1 Polymorphisms Analysis Shows Their Genetic Susceptibility for Meningioma Risk and the Association with Tumor-Related Phenotype in a Chinese Population.
Huang G; Feng J; Hao S; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
World Neurosurg; 2018 Jun; 114():e883-e891. PubMed ID: 29581016
[TBL] [Abstract][Full Text] [Related]
39. A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
Kote-Jarai Z; Jugurnauth S; Mulholland S; Leongamornlert DA; Guy M; Edwards S; Tymrakiewitcz M; O'Brien L; Hall A; Wilkinson R; Al Olama AA; Morrison J; Muir K; Neal D; Donovan J; Hamdy F; Easton DF; Eeles R; ;
Br J Cancer; 2009 Jan; 100(2):426-30. PubMed ID: 19127258
[TBL] [Abstract][Full Text] [Related]
40. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
